| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
|
N Engl J Med
|
2013
|
6.21
|
|
2
|
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
|
Lancet Oncol
|
2010
|
4.10
|
|
3
|
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
|
Blood
|
2008
|
2.74
|
|
4
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
|
Blood
|
2006
|
2.51
|
|
5
|
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
|
Blood
|
2012
|
2.42
|
|
6
|
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
|
Blood
|
2005
|
1.97
|
|
7
|
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
|
Blood
|
2011
|
1.94
|
|
8
|
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
|
J Clin Oncol
|
2011
|
1.78
|
|
9
|
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
|
J Clin Oncol
|
2008
|
1.53
|
|
10
|
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
|
Blood
|
2002
|
1.21
|
|
11
|
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
|
Blood
|
2012
|
1.19
|
|
12
|
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
|
Blood
|
2009
|
1.10
|
|
13
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
|
Haematologica
|
2008
|
1.06
|
|
14
|
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
|
Blood
|
2011
|
1.03
|
|
15
|
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
|
Blood
|
2014
|
0.96
|
|
16
|
Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production.
|
J Inorg Biochem
|
2011
|
0.92
|
|
17
|
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
|
Leuk Lymphoma
|
2010
|
0.90
|
|
18
|
Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.
|
Eur J Haematol
|
2010
|
0.86
|
|
19
|
Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
|
Int J Hematol
|
2007
|
0.85
|
|
20
|
The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma.
|
Haematologica
|
2006
|
0.84
|
|
21
|
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
|
Am J Pathol
|
2012
|
0.84
|
|
22
|
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
|
Leuk Lymphoma
|
2013
|
0.83
|
|
23
|
Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
|
Leuk Lymphoma
|
2002
|
0.81
|
|
24
|
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
|
Clin Cancer Res
|
2004
|
0.80
|
|
25
|
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
|
Int J Hematol
|
2011
|
0.78
|
|
26
|
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.
|
Br J Haematol
|
2013
|
0.76
|
|
27
|
Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer.
|
Tumori
|
2007
|
0.75
|
|
28
|
[Successful autologous peripheral blood stem cell transplantation in a case of IgM myeloma].
|
Med Clin (Barc)
|
2002
|
0.75
|
|
29
|
[Hemorrhagic complications after treatment with defibrotide in a case of severe veno-occlusive disease].
|
Med Clin (Barc)
|
2002
|
0.75
|